Piramal Pharma Limited PPLPHARMA NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.piramalpharma.com

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.

Market & Price

Market Cap

₹22,890.25 Cr

Current Price

₹172.79

High / Low (52W)

₹216.88 / ₹133.27

Beta

0.37

Valuation

Stock P/E

Industry PE

37.60

Forward P/E

39.89

PEG Ratio

Book Value

₹61.03

Price to Book

2.83

P/S

2.58

EV/EBITDA

29.82

Dividend Yield

0.08%

Profitability & Returns

ROCE

1.25%

ROE

-4.00%

ROA

0.34%

Profit Margin

-3.67%

Op Margin

8.80%

EPS (Latest Qtr)

₹-0.07

EPS (TTM)

₹-2.45

Balance Sheet & Liquidity

Debt/Equity

0.70

Quick Ratio

0.74

Current Ratio

1.51

Debt

₹5,674.59 Cr

Total Assets

₹17,965.04 Cr

Current Assets

₹7,191.66 Cr

Working Capital

₹2,433.38 Cr

Ownership

Promoter Holding

54.54%

Chg in Prom Hold

FII / Inst Holding

21.02%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

₹26,090.71 Cr

Total Revenue (TTM)

₹8,869.08 Cr

EBITDA

₹874.84 Cr

Free Cash Flow

₹674.74 Cr

Operating Cash Flow

₹1,652.59 Cr

Shares Outstanding

₹132.47 Cr

Gross Margin

63.48%

Payout Ratio

15.07%

Growth (CAGR)

Revenue 5Y

8.04%

Profit 5Y

-24.93%

Revenue (YoY)

-0.10%

Earnings (YoY)

PROS

Generates positive free cash flow.

CONS

Earnings shrank at -24.9% CAGR over 5 years.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PPLPHARMA Piramal Pharma Limited NIFTY_SMALLNSEPHARMA	172.79	-	₹22,890.25 Cr	0.08%	1.25%	-4.00%	8.04%	-24.93%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	2,204.22 Cr	2,754.07 Cr	1,933.71 Cr	2,139.87 Cr	2,751.77 Cr
Cost of Revenue	805.83 Cr	954.98 Cr	694.05 Cr	786.31 Cr	1,055.67 Cr
Gross Profit	1,398.39 Cr	1,799.09 Cr	1,239.66 Cr	1,353.56 Cr	1,696.10 Cr
Operating Expenses	1,257.46 Cr	1,480.86 Cr	1,330.24 Cr	1,370.57 Cr	1,453.97 Cr
Operating Income	140.93 Cr	318.23 Cr	-90.58 Cr	-17.01 Cr	242.13 Cr
EBITDA	366.92 Cr	619.24 Cr	204.41 Cr	208.12 Cr	344.37 Cr
Interest Expense	103.31 Cr	103.68 Cr	86.15 Cr	89.24 Cr	82.99 Cr
Pretax Income	66.80 Cr	272.80 Cr	-79.02 Cr	-93.86 Cr	43.00 Cr
Tax Provision	63.12 Cr	119.30 Cr	2.68 Cr	42.33 Cr	51.83 Cr
Net Income	3.68 Cr	153.50 Cr	-81.70 Cr	-136.19 Cr	-8.82 Cr
Diluted EPS	0.03	1.16	-0.62	-1.03	-0.07

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	7,032.41 Cr	8,106.41 Cr	9,151.18 Cr	8,869.08 Cr
Cost of Revenue	-	3,000.18 Cr	3,258.76 Cr	3,231.65 Cr	3,238.54 Cr
Gross Profit	-	4,032.23 Cr	4,847.65 Cr	5,919.53 Cr	5,630.54 Cr
Operating Expenses	-	4,080.20 Cr	4,385.62 Cr	5,291.04 Cr	5,540.16 Cr
Operating Income	-	-47.97 Cr	462.03 Cr	628.49 Cr	90.38 Cr
EBITDA	-	894.25 Cr	1,366.81 Cr	1,652.57 Cr	995.98 Cr
Interest Expense	-	337.71 Cr	446.95 Cr	421.59 Cr	340.80 Cr
Pretax Income	-	-120.15 Cr	179.29 Cr	414.64 Cr	-176.06 Cr
Tax Provision	-	66.31 Cr	161.47 Cr	323.51 Cr	149.88 Cr
Net Income	-	-186.46 Cr	17.82 Cr	91.13 Cr	-325.94 Cr
Diluted EPS	-	-1.54	0.14	0.68	-2.46

Compounded Sales Growth

5 Years:	8.04%
1 Year:	-0.10%

Compounded Profit Growth

5 Years:	-24.93%
1 Year:	-

Stock Price Performance

1 Year:	-15.69%
6 Months:	-6.53%
3 Months:	+8.35%
1 Month:	+6.75%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	14,522.56 Cr	15,311.81 Cr	15,677.59 Cr	17,965.04 Cr
Current Assets	-	4,835.48 Cr	5,464.47 Cr	5,796.99 Cr	7,191.66 Cr
Cash & Equivalents	-	195.59 Cr	356.82 Cr	368.98 Cr	1,199.88 Cr
Inventory	-	1,681.37 Cr	2,175.88 Cr	2,312.70 Cr	3,064.44 Cr
Receivables	-	1,799.34 Cr	2,134.43 Cr	2,349.52 Cr	2,157.67 Cr
Total Liabilities	-	7,749.06 Cr	7,400.44 Cr	7,552.12 Cr	9,802.42 Cr
Current Liabilities	-	3,843.05 Cr	4,369.30 Cr	3,766.27 Cr	4,758.28 Cr
Long Term Debt	-	3,383.54 Cr	2,483.75 Cr	3,214.07 Cr	4,299.97 Cr
Total Debt	-	5,637.08 Cr	4,710.16 Cr	4,856.47 Cr	5,674.59 Cr
Total Equity	-	6,773.50 Cr	7,911.34 Cr	8,125.41 Cr	8,162.62 Cr
Shares Outstanding	-	122.19 Cr	132.29 Cr	132.57 Cr	132.92 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	483.89 Cr	1,004.54 Cr	892.30 Cr	1,652.59 Cr
Investing Cash Flow	-	-1,338.78 Cr	-434.01 Cr	-477.46 Cr	-826.03 Cr
Financing Cash Flow	-	817.79 Cr	-422.34 Cr	-440.83 Cr	-38.98 Cr
Capital Expenditure	-	-964.75 Cr	-712.04 Cr	-664.38 Cr	-890.02 Cr
Free Cash Flow	-	-480.86 Cr	292.50 Cr	227.92 Cr	762.57 Cr
Net Change in Cash	-	-37.10 Cr	148.19 Cr	-25.99 Cr	787.58 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	57.3%	59.8%	64.7%	63.5%
Operating Margin %	-	-0.7%	5.7%	6.9%	1.0%
Net Margin %	-	-2.7%	0.2%	1.0%	-3.7%
ROE %	-	-2.8%	0.2%	1.1%	-4.0%
ROCE %	-	-0.4%	4.2%	5.3%	0.7%

Shareholding Pattern

Insiders

54.54%

Institutions

21.02%

Public Float

46.23%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PPLPHARMA

No recent headlines available.

PPLPHARMA · Healthcare